Table 1 Percentage of PS amplitude values of BST and LTP recorded in the CA1 region of hippocampal slices from the control group and groups treated with different substances at different times.

From: Molecular mechanisms at the basis of the protective effect exerted by EPPS on neurodegeneration induced by prefibrillar amyloid oligomers

Time (min)

CTRL (PS% Amplitude)

sCT-NA (PS% Amplitude)

sCT-PFOs (PS% Amplitude)

EPPS (PS%Amplitude)

EPPS + sCT-PFOs (PS% Amplitude)

Significance between groups at different times

12–16

101.1 ± 5.8

102.8 ± 8.4

99 ± 8.2

103.8 ± 6.7

100.3 ± 3.7

no significance

52–56

102.9 ± 7.7

101.6 ± 7.7

99.7 ± 7.9

144.8 ± 11.7

137.4 ± 6.3

CTRL vs. EPPS, *p < 0.05;

NA vs. EPPS, *p < 0.05;

PFOs vs. EPPS, **p < 0.01

73–77

Before HFS

98.3 ± 7.5

116.4 ± 9.9

88.3 ± 7.5

182.6 ± 16.9

170.7 ± 18.6

CTRL vs. EPPS, ***p < 0.001;

CTRL vs. EPPS + PFOs, *p < 0.05;

NA vs. EPPS, *p < 0.05;

PFOs vs. EPPS, ***p < 0.001;

PFOs vs. EPPS + PFOs **p < 0.01

80–84 After HFS

318.6 ± 14.2

242.0 ± 7.5

216.2 ± 15.8

330.9 ± 24.7

308.7 ± 27.8

CTRL vs. PFOs, *p < 0.05;

NA vs. EPPS *p < 0.05;

PFOs vs. EPPS ***p < 0.001; PFOs vs. EPPS + PFOs *p < 0.05

140–144

261.3 ± 10.3

188.9 ± 6.1

109.3 ± 8.9

267.2 ± 19.7

255.9 ± 20.3

CTRL vs. PFOs, **p < 0.001;

NA vs. PFOs, *p < 0.05;

NA vs. EPPS, *p < 0.05;

PFOs vs. EPPS, **p < 0.001; PFOs vs. EPPS + PFOs, **p < 0.001

166–170

221.6 ± 10.0

192.1 ± 12.8

106.6 ± 10.1

250.9 ± 18.9

222.8 ± 20.6

CTRL vs. PFOs, **p < 0.001;

NA vs. PFOs, *p < 0.05;

PFOs vs. EPPS, **p < 0.001;

PFOs vs. EPPS + PFOs, **p < 0.001

  1. PS population spikes, BST basal synaptic transmission, LTP long-term potentiation, CTRL control group, EPPS 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid, PFOs prefibrillar oligomers.
  2. *p < 0.05; **p < 0.01; ***p < 0.001.
Back to article page